カイダ　ケンイチ   KAIDA Kenichi   海田　賢一    所属   埼玉医科大学  医学部 総合医療センター　脳神経内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Original research: Second IVIg course in Guillain-Barré syndrome with poorprognosis: the non-randomised ISID study
掲載誌名	正式名：Journal of Neurology, Neurosurgery&Psychiatry ISSNコード：00223050
出版社	BMJ
巻・号・頁	91(2),113-121頁
著者・共著者	Christine Verboon,Bianca van den Berg,David R Cornblath,Esmee Venema,Kenneth C Gorson,Michael P Lunn,Hester Lingsma,Peter Van den Bergh,Thomas Harbo,Kathleen Bateman,Yann Pereon,Søren H Sindrup,Susumu Kusunoki,James Miller,Zhahirul Islam,Hans-Peter Hartung,Govindsinh Chavada,Bart C Jacobs,Richard A C Hughes,Pieter A van Doorn
発行年月	2020/02
概要	<sec><title>Objective</title>To compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses.</sec><sec><title>Methods</title>From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression.</sec><sec><title>Results</title>Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an ‘early’ second IVIg course (1–2 weeks after start of the first IVIg course) and 18 patients a ‘late’ second IVIg course (2–4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary e
DOI	10.1136/jnnp-2019-321496
PermalinkURL	https://syndication.highwire.org/content/doi/10.1136/jnnp-2019-321496